MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Active Stand: 2024-12-12 |
{
"resourceType" : "ConceptMap",
"id" : "mii-cm-onko-atc-transitions-2024",
"meta" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
"valueCode" : "CC-BY-4.0"
},
{
"extension" : [
{
"url" : "packageId",
"valueId" : "de.medizininformatikinitiative.kerndatensatz.onkologie"
},
{
"url" : "version",
"valueString" : "2027.0.0-ballot.1"
},
{
"url" : "uri",
"valueUri" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
}
],
"url" : "http://hl7.org/fhir/StructureDefinition/package-source"
}
],
"profile" : [
🔗 "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap"🔗 ,
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"
]
},
"language" : "de",
"text" : {
"status" : "generated",
"div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2024</b></p><a name=\"de-mii-cm-onko-atc-transitions-2024\"> </a><a name=\"de-hcmii-cm-onko-atc-transitions-2024\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profiles: <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-shareableconceptmap.html\">CRMI Shareable ConceptMap</a>, <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-publishableconceptmap.html\">CRMI Publishable ConceptMap</a></p></div><p>Mapping from <a href=\"ValueSet-mii-vs-onko-systemische-therapie-substanzen-2023.html\">MII VS Onkologie Systemische Therapie Substanzen ATC 2023</a> to <a href=\"ValueSet-mii-vs-onko-systemische-therapie-substanzen-2024.html\">MII VS Onkologie Systemische Therapie Substanzen ATC 2024</a></p><br/><p>Mapping from <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc) to <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc)</p><table class=\"grid\"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td><td><b>Comment</b></td></tr><tr><td>L04AA34 (Alemtuzumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AG06 (Alemtuzumab)</td><td>Reklassifizierung innerhalb der Immunsuppressiva</td></tr><tr><td>L04AA26 (Belimumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AG04 (Belimumab)</td><td/></tr><tr><td>L04AA25 (Eculizumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AJ01 (Eculizumab)</td><td>Reklassifizierung zu Komplement-Inhibitoren</td></tr><tr><td>L04AA21 (Efalizumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AG02 (Efalizumab)</td><td/></tr><tr><td>L01EG02 (Everolimus)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AH02 (Everolimus)</td><td>Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)</td></tr><tr><td>L04AA27 (Fingolimod)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AE01 (Fingolimod)</td><td>Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren</td></tr><tr><td>L04AA13 (Leflunomid)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AK01 (Leflunomid)</td><td/></tr><tr><td>L01FX24 (Mosunetuzumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FX25 (Mosunetuzumab)</td><td>Code-Anpassung innerhalb der bispezifischen Antikörper</td></tr><tr><td>L04AA02 (Muromonab-CD3)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AG01 (Muromonab-CD3)</td><td/></tr><tr><td>L04AA23 (Natalizumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AG03 (Natalizumab)</td><td/></tr><tr><td>L01XY03 (Nivolumab und Relatlimab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FY02 (Nivolumab und Relatlimab)</td><td>Reklassifizierung zu Kombinationen monoklonaler Antikörper</td></tr><tr><td>L01FA02 (Ofatumumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AG12 (Ofatumumab)</td><td>Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)</td></tr><tr><td>L01XY02 (Pertuzumab und Trastuzumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FY01 (Pertuzumab und Trastuzumab)</td><td>Reklassifizierung zu Kombinationen monoklonaler Antikörper</td></tr><tr><td>L04AA10 (Sirolimus)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L04AH01 (Sirolimus)</td><td>Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)</td></tr></table></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "shareable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "publishable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
"code" : "package",
"display" : "Package"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
"valueDate" : "2026-09-15"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-topic",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C3262"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"telecom" : [
{
"system" : "email",
"value" : "thomas.debertshaeuser@charite.de"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-editor",
"valueContactDetail" : {
"name" : "Taskforce Core Data Set"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
"valueCoding" : {
"system" : "http://hl7.org/fhir/version-algorithm",
"code" : "semver",
"display" : "SemVer"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
"valuePeriod" : {
"start" : "2027"
}
}
],
"url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2024",
"version" : "2027.0.0-ballot.1",
"name" : "MII_CM_Onko_ATC_Transitions_2024",
"title" : "MII CM Onko ATC Code Changes 2023 to 2024",
"status" : "active",
"experimental" : false,
"date" : "2024-12-12",
"publisher" : "Medizininformatik Initiative",
"contact" : [
{
"name" : "Medizininformatik Initiative",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/"
}
]
}
],
"description" : "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2023 zu 2024. Mehrere immunmodulatorische Substanzen wurden in neue Kategorien umklassifiziert, und Kombinationspräparate erhielten neue Codes.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "DE",
"display" : "Germany"
}
]
}
],
"purpose" : "Migration von ATC-Codes für immunmodulatorische Substanzen und Kombinationspräparate, die 2024 umkodiert wurden.",
"sourceCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2023",
"targetCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2024",
"group" : [
{
"source" : "http://fhir.de/CodeSystem/bfarm/atc",
"target" : "http://fhir.de/CodeSystem/bfarm/atc",
"element" : [
{
"code" : "L04AA34",
"display" : "Alemtuzumab",
"target" : [
{
"code" : "L04AG06",
"display" : "Alemtuzumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung innerhalb der Immunsuppressiva"
}
]
},
{
"code" : "L04AA26",
"display" : "Belimumab",
"target" : [
{
"code" : "L04AG04",
"display" : "Belimumab",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L04AA25",
"display" : "Eculizumab",
"target" : [
{
"code" : "L04AJ01",
"display" : "Eculizumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Komplement-Inhibitoren"
}
]
},
{
"code" : "L04AA21",
"display" : "Efalizumab",
"target" : [
{
"code" : "L04AG02",
"display" : "Efalizumab",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01EG02",
"display" : "Everolimus",
"target" : [
{
"code" : "L04AH02",
"display" : "Everolimus",
"equivalence" : "equivalent",
"comment" : "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)"
}
]
},
{
"code" : "L04AA27",
"display" : "Fingolimod",
"target" : [
{
"code" : "L04AE01",
"display" : "Fingolimod",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren"
}
]
},
{
"code" : "L04AA13",
"display" : "Leflunomid",
"target" : [
{
"code" : "L04AK01",
"display" : "Leflunomid",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01FX24",
"display" : "Mosunetuzumab",
"target" : [
{
"code" : "L01FX25",
"display" : "Mosunetuzumab",
"equivalence" : "equivalent",
"comment" : "Code-Anpassung innerhalb der bispezifischen Antikörper"
}
]
},
{
"code" : "L04AA02",
"display" : "Muromonab-CD3",
"target" : [
{
"code" : "L04AG01",
"display" : "Muromonab-CD3",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L04AA23",
"display" : "Natalizumab",
"target" : [
{
"code" : "L04AG03",
"display" : "Natalizumab",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XY03",
"display" : "Nivolumab und Relatlimab",
"target" : [
{
"code" : "L01FY02",
"display" : "Nivolumab und Relatlimab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Kombinationen monoklonaler Antikörper"
}
]
},
{
"code" : "L01FA02",
"display" : "Ofatumumab",
"target" : [
{
"code" : "L04AG12",
"display" : "Ofatumumab",
"equivalence" : "equivalent",
"comment" : "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)"
}
]
},
{
"code" : "L01XY02",
"display" : "Pertuzumab und Trastuzumab",
"target" : [
{
"code" : "L01FY01",
"display" : "Pertuzumab und Trastuzumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Kombinationen monoklonaler Antikörper"
}
]
},
{
"code" : "L04AA10",
"display" : "Sirolimus",
"target" : [
{
"code" : "L04AH01",
"display" : "Sirolimus",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)"
}
]
}
]
}
]
}